

Ref. No: 2296  
Date: 15/01/26  
Subject: Acute Myeloid Leukaemia (AML) Patients

## REQUEST & RESPONSE

### FOI Request: Acute Myeloid Leukaemia (AML) Patients

1. How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months

Diagnosed between 01.12.24 and 30.11.25	
Primary AML	26
Progression AML	<5

1. How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months - **27**

- a. Of these patients how many are refractory/relapsed (R/R)? - **1**
- b. How many of the R/R patients were FLT3 positive? - **0**

2. How many patients have been treated for AML in the latest 12 months with the following treatments

- Venetoclax with azacitidine - **19**
- Midostaurin - **<5**
- Quizartinib - **<5**
- Gemtuzumab - **<5**
- Ivosidenib with azacitidine - **<5**
- Liposomal cytarabine–daunorubicin - **<5**
- Oral azacitidine - **0**
- Gilteritinib - **<5**
- Palliative care – not measurable
- Enrolled in a clinical trial - **0**

3. How many relapsed/refractory patients have been treated for AML in the last 12 months with the following treatments (This question relates to treatments administered to relapsed/refractory AML patients)

in clinical practice, regardless of licence status or funding route (including any off-label use). - 0

- Venetoclax with azacitidine
- Midostaurin
- Quizartinib
- Gemtuzumab
- Ivosidenib with azacitidine
- Liposomal cytarabine–daunorubicin
- Oral azacitidine
- Gilteritinib
- Palliative care
- Enrolled in a clinical trial

4. Of your AML patient how many were tested as below in the last 12 months

- Received an FLT3 mutation test when they were diagnosed - 22
- Received an FLT3 mutation test when their disease relapsed
- Received an FLT3 mutation test when their disease became refractory